Royal Bank Of Canada Issues Positive Forecast for Exelixis (NASDAQ:EXEL) Stock Price

Exelixis (NASDAQ:EXEL) had its price target boosted by stock analysts at Royal Bank Of Canada from $51.00 to $58.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has a “sector perform” rating on the biotechnology company’s stock. Royal Bank Of Canada‘s price objective would suggest a potential downside of 19.03% from the stock’s current price.

Several other equities research analysts have also recently commented on EXEL. Wells Fargo & Company boosted their price target on Exelixis from $40.00 to $49.00 and gave the company an “equal weight” rating in a research note on Monday, July 13th. Citigroup restated a “market outperform” rating on shares of Exelixis in a research note on Monday, October 19th. William Blair reaffirmed an “outperform” rating on shares of Exelixis in a report on Friday, September 11th. Leerink Partners downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating and set a $52.00 price objective on the stock. in a research note on Thursday, August 6th. Finally, Zacks Research upgraded shares of Exelixis from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 1st. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Exelixis currently has a consensus rating of “Hold” and an average target price of $53.21.

Exelixis Stock Performance

Shares of EXEL traded up $5.43 during mid-day trading on Friday, reaching $71.63. 1,367,105 shares of the company’s stock traded hands, compared to its average volume of 2,570,686. Exelixis has a 12 month low of $36.00 and a 12 month high of $71.87. The stock has a market capitalization of $17.75 billion, a P/E ratio of 22.59, a price-to-earnings-growth ratio of 1.86 and a beta of 0.47. The business’s 50-day moving average price is $59.07 and its 200-day moving average price is $50.79.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Thursday, October 29th. The biotechnology company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.05. Exelixis had a return on equity of 42.17% and a net margin of 35.33%. The business had revenue of $658.70 million during the quarter, compared to analyst estimates of $646.51 million. During the same quarter in the prior year, the firm posted $0.78 earnings per share. The company’s revenue was up 10.2% on a year-over-year basis. Equities research analysts anticipate that Exelixis will post 3.19 EPS for the current year.

Insider Activity at Exelixis

In other news, Director Mary Beckerle sold 9,812 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $53.66, for a total value of $526,511.92. Following the transaction, the director owned 16,079 shares of the company’s stock, valued at $862,799.14. This represents a 37.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On Exelixis

A number of institutional investors have recently made changes to their positions in the stock. Arkadios Wealth Advisors acquired a new stake in shares of Exelixis in the 1st quarter valued at approximately $476,000. Corient Private Wealth LP bought a new stake in Exelixis in the second quarter valued at approximately $4,324,000. L2 Asset Management LLC bought a new stake in Exelixis in the second quarter valued at approximately $6,839,000. BlackRock Inc. acquired a new stake in Exelixis in the second quarter worth $1,581,991,000. Finally, JLB & Associates Inc. acquired a new stake in Exelixis in the second quarter worth $2,658,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis News Summary

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Q3 earnings and revenue exceeded expectations. Exelixis reported non-GAAP earnings of $0.94 per share, above the $0.89 consensus estimate, while revenue reached $658.7 million versus expectations of approximately $646.5 million. Revenue grew 10.2% year over year, with CABOMETYX continuing to drive performance. Exelixis Q3 Earnings Report
• Positive Sentiment: Pipeline progress provides a potential catalyst. Exelixis said the FDA has assigned a March 3, 2027 PDUFA date for zanzalintinib, giving investors a defined timeline for a regulatory decision. The company is also advancing Wave 2 pivotal development plans, which could expand its future growth opportunities. Zanzalintinib PDUFA and Wave 2 Plans
• Positive Sentiment: Profitability and cash generation remained strong. Third-quarter net income increased year over year, and operating cash flow totaled about $280 million, reinforcing Exelixis’ ability to fund its commercial operations and pipeline.
• Neutral Sentiment: Institutional positioning was mixed. Recent filings showed significant purchases by some quantitative and institutional investors, while other large managers reduced their holdings. This signals differing views on the stock’s valuation and outlook.
• Negative Sentiment: Barclays remains cautious on valuation. The firm raised its price target from $49 to $54 but maintained an “equal weight” rating. The new target remains materially below the recent trading level, suggesting limited near-term upside in Barclays’ view.
• Negative Sentiment: Reported insider activity has been entirely selling. Data cited in recent coverage showed six insider sales and no purchases during the past six months. While these transactions may be routine, they can weigh on investor sentiment when the stock is near a 52-week high.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer and other serious diseases. The company’s research programs center primarily on targeted therapies, including treatments designed to inhibit signaling pathways involved in tumor growth and progression.

Exelixis’ lead product is CABOMETYX (cabozantinib), an oral medicine approved in the United States for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer.